News

Rubrik Inc. (RBRK) stock received a Buy rating and a $77 price target from Rosenblatt analyst Blair Abernethy, citing the company's strong product position and growth potential in the data management and security markets. This upgrade comes ahead of Rubrik's fourth-quarter fiscal 2025 earnings report, expected to show continued revenue growth and a shift towards subscription-based services.

ViiV Healthcare's EMBRACE phase 2b study found that N6LS, a novel long-acting HIV capsid inhibitor, effectively suppressed viral levels in adults living with HIV when combined with monthly cabotegravir long-acting. The company also presented positive data from two phase 2a studies of investigational antiretroviral therapies, VH184 and VH499.

Dyne Therapeutics, a company developing therapies for neuromuscular diseases, has initiated a global Registrational Expansion Cohort for its lead candidate DYNE-101 in patients with myotonic dystrophy type 1. The company aims to submit for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.

Adobe surpassed analysts' estimates in its first-quarter report with a revenue of $5.71 billion and adjusted earnings of $5.08 per share, reflecting year-over-year increases across its segments. However, despite positive results and reaffirmed long-term goals, Adobe's shares fell by over 3% in after-hours trading.

UiPath's fourth-quarter earnings report revealed a mixed bag of results, with the company exceeding earnings expectations but falling short on revenue. While this led to a significant drop in share price after hours, the company's focus on innovation and strategic acquisitions like Peak, an AI-native company, suggest a continued commitment to growth and leadership in the automation space.